Combining systemic inflammatory response index and albumin fibrinogen ratio to predict early serious complications and prognosis after resectable gastric cancer

Table 2 Patient baseline characteristics and differences in each variable across subgroups of postoperative complications after respectable gastric cancer

Variables		Minor/no complication, n = 479 (84.3%)	Major complication, n = 89 (15.7%)	P value
					Sex
Male	378 (78.9)	64 (71.9)	0.1441
Female	101 (21.1)	25 (28.1)
Age in yr		59.93 ± 9.66	62.19 ± 10.33	0.0462,a
Underlying disease	No	382 (79.7)	75 (84.3)	0.3231
	Yes	97 (20.3)	14 (15.7)
BMI		22.37 ± 3.36	21.23 ± 3.28	0.0032,a
Tumor location	Upper third	56 (11.7)	15 (16.9)	0.5371
	Middle third	44 (9.2)	8 (9.0)
	Lower third	377 (78.7)	66 (74.2)
Tumor dimensions in cm	< 3	148 (30.9)	16 (18.0)	0.0141,a
	≥ 3	331 (69.1)	73 (82.0)
Differentiation	Moderate and poor	460 (96.0)	86 (96.6)	11
	Well	19 (4.0)	3 (3.4)
TNM stage	I	106 (22.1)	13 (14.6)	0.2361
	II	150 (31.3)	28 (31.5)
	III	223 (46.6)	48 (53.9)
Surgical approach	Open	149 (31.1)	31 (34.8)	0.5391
	Laparoscopic	190 (39.7)	37 (41.6)
	Robot-assisted	140 (29.2)	21 (23.6)
Operation	Subtotal gastrectomy	248 (51.8)	34 (38.2)	0.0191,a
	Total gastrectomy	231 (48.2)	55 (61.8)
ASA	I-II	433 (90.4)	76 (85.4)	0.1551
	III-IV	46 (9.6)	13 (14.6)
Blood loss in mL		100 (100)	150 (200)	0.0893
Duration of surgery in min		240 (90)	250 (85)	0.0793
Perioperative transfusion	No	389 (81.2)	50 (56.2)	< 0.0011,a
	Yes	90 (18.8)	39 (43.8)
Length of hospitalization in d		17.00 (5.00)	21.00 (8.00)	< 0.0013,a
Lymph node metastasis rate, %		4.02% ± 15.17%	4.52% ± 14.72%	0.2642
Lymphocytes as × 109/L		1.44 (0.72)	1.18 (0.59)	< 0.0013,a
Neutrophils as × 109/L		3.52 (1.76)	5.03 (1.56)	< 0.0013,a
Platelet as × 109/L		213 (86)	234 (107)	0.0133,a
Monocyte as × 109/L		0.39 (0.16)	0.42 (0.17)	0.0323,a
Albumin in g/L		39.40 ± 4.36	36.60 ± 4.50	< 0.0012,a
Fibrinogen in g/L		3.39 ± 0.79	4.08 ± 1.04	< 0.0012,a
SIRI		0.95 (0.82)	1.54 (0.97)	< 0.0013,a
AFR		12.32 ± 3.46	9.54 ± 2.68	< 0.0013,a
CA199 in ng/mL	Negative	406 (84.8)	69 (77.5)	0.0901
	Positive	73 (15.2)	20 (22.5)
CEA in ng/mL	Negative	386 (80.6)	61 (68.5)	0.0111,a
	Positive	93 (19.4)	28 (31.5)

^aP < 0.05.

¹χ² test.

²Student’s t-test with mean ± standard deviation.

³Mann-Whitney U test with median (interquartile range).

AFR: Albumin fibrinogen ratio; ASA: American Society of Anesthesiology; BMI: Body mass index; CA199: Carbohydrate antigen 199; CEA: Carcinoembryonic antigen; SIRI: Systemic inflammation response index; TNM: Tumor-node-metastasis.